| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Section of Retroviral Immunology and
Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892;
AIDS Vaccine Program, Science Applications International Corp., National Cancer Institute, Frederick, MD 21702;
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
Oligodeoxynucleotides containing CpG motifs (CpG ODNs) mimic microbial DNA and activate effectors of the innate immune response, which limits the spread of pathogens and promotes an adaptive immune response. CpG ODNs have been shown to protect mice from infection with intracellular pathogens. Unfortunately, CpG motifs that optimally stimulate humans are only weakly active in mice, mandating the use of nonhuman primates to monitor the activity and safety of "human" CpG ODNs in vivo. This study demonstrates that CpG ODN treatment of rhesus macaques significantly reduces the severity of the lesions caused by a challenge with Leishmania. Leishmania superinfection is common in immunocompromised hosts, particularly those infected with HIV. This study shows that PBMCs from HIV-infected subjects respond to stimulation with CpG ODNs. To determine whether CpG ODNs can protect retrovirus-infected primates, SIV-infected macaques were treated with CpG ODNs and then challenged with Leishmania. Both lesion size and parasite load were significantly reduced in the CpG-treated animals. These findings support the clinical development of CpG ODNs as immunoprotective agents in normal and HIV-infected patients.
This article has been cited by other articles:
|
|
 |
|
  V. A. Stewart, S. McGrath, A. M. Krieg, N. S. Larson, E. Angov, C. L. Smith, T. G. Brewer, and D. G. Heppner Jr. Activation of Innate Immunity in Healthy Macaca mulatta Macaques by a Single Subcutaneous Dose of GMP CpG 7909: Safety Data and Interferon-Inducible Protein-10 Kinetics for Humans and Macaques Clin. Vaccine Immunol., February 1, 2008; 15(2): 221 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Krieg Antiinfective Applications of Toll-like Receptor 9 Agonists Proceedings of the ATS, July 1, 2007; 4(3): 289 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Teleshova, J. Kenney, G. Van Nest, J. Marshall, J. D. Lifson, I. Sivin, J. Dufour, R. Bohm, A. Gettie, and M. Robbiani Local and Systemic Effects of Intranodally Injected CpG-C Immunostimulatory-Oligodeoxyribonucleotides in Macaques J. Immunol., December 15, 2006; 177(12): 8531 - 8541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Puig, A. Grajkowski, M. Boczkowska, C. Ausin, S. L. Beaucage, and D. Verthelyi Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates Nucleic Acids Res., December 2, 2006; 34(22): 6488 - 6495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Pedras-Vasconcelos, D. Goucher, M. Puig, L. H. Tonelli, V. Wang, S. Ito, and D. Verthelyi CpG oligodeoxynucleotides protect newborn mice from a lethal challenge with the neurotropic tacaribe arenavirus. J. Immunol., April 15, 2006; 176(8): 4940 - 4949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Waag, M. J. McCluskie, N. Zhang, and A. M. Krieg A CpG Oligonucleotide Can Protect Mice from a Low Aerosol Challenge Dose of Burkholderia mallei Infect. Immun., March 1, 2006; 74(3): 1944 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Teleshova, J. Kenney, V. Williams, G. Van Nest, J. Marshall, J. D. Lifson, I. Sivin, J. Dufour, R. Bohm, A. Gettie, et al. CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques J. Leukoc. Biol., February 1, 2006; 79(2): 257 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. M. Kraft, T. Arndt, K. J. Hasenkrug, and U. Dittmer Effective treatment of retrovirus-induced suppression of antibody responses with CpG oligodeoxynucleotides J. Gen. Virol., December 1, 2005; 86(12): 3365 - 3368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, K. Abel, K. Lantz, A. M. Krieg, M. B. McChesney, and C. J. Miller The Toll-Like Receptor 7 (TLR7) Agonist, Imiquimod, and the TLR9 Agonist, CpG ODN, Induce Antiviral Cytokines and Chemokines but Do Not Prevent Vaginal Transmission of Simian Immunodeficiency Virus When Applied Intravaginally to Rhesus Macaques J. Virol., November 15, 2005; 79(22): 14355 - 14370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ito, J. Pedras-Vasconcelos, and D. M. Klinman CpG Oligodeoxynucleotides Increase the Susceptibility of Normal Mice to Infection by Candida albicans Infect. Immun., September 1, 2005; 73(9): 6154 - 6156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Flynn, V. Wang, D. L. Sacks, R. A Seder, and D. Verthelyi Prevention and Treatment of Cutaneous Leishmaniasis in Primates by Using Synthetic Type D/A Oligodeoxynucleotides Expressing CpG Motifs Infect. Immun., August 1, 2005; 73(8): 4948 - 4954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Abel, Y. Wang, L. Fritts, E. Sanchez, E. Chung, P. Fitzgerald-Bocarsly, A. M. Krieg, and C. J. Miller Deoxycytidyl-Deoxyguanosine Oligonucleotide Classes A, B, and C Induce Distinct Cytokine Gene Expression Patterns in Rhesus Monkey Peripheral Blood Mononuclear Cells and Distinct Alpha Interferon Responses in TLR9-Expressing Rhesus Monkey Plasmacytoid Dendritic Cells Clin. Vaccine Immunol., May 1, 2005; 12(5): 606 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Jiang, M. M. Lederman, J. R. Salkowitz, B. Rodriguez, C. V. Harding, and S. F. Sieg Impaired Monocyte Maturation in Response to CpG Oligodeoxynucleotide Is Related to Viral RNA Levels in Human Immunodeficiency Virus Disease and Is at Least Partially Mediated by Deficiencies in Alpha/Beta Interferon Responsiveness and Production J. Virol., April 1, 2005; 79(7): 4109 - 4119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. B. Bekeredjian-Ding, M. Wagner, V. Hornung, T. Giese, M. Schnurr, S. Endres, and G. Hartmann Plasmacytoid Dendritic Cells Control TLR7 Sensitivity of Naive B Cells via Type I IFN J. Immunol., April 1, 2005; 174(7): 4043 - 4050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kumar, T. R. Jones, M. S. Oakley, H. Zheng, S. P. Kuppusamy, A. Taye, A. M. Krieg, A. W. Stowers, D. C. Kaslow, and S. L. Hoffman CpG Oligodeoxynucleotide and Montanide ISA 51 Adjuvant Combination Enhanced the Protective Efficacy of a Subunit Malaria Vaccine Infect. Immun., February 1, 2004; 72(2): 949 - 957. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
